Sign In
Buy ANIK
$14.41
+0.0300 (+0.209%)
At Close: Jun 03, 2026
Bullish On Anika Therapeutics's Pullback As Integrity Scales
11:21am, Thursday, 30'th Apr 2026
Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK's Integrity recei
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
11:31am, Wednesday, 29'th Apr 2026
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Reports First Quarter 2026 Financial Results
07:05am, Wednesday, 29'th Apr 2026
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execut
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
04:01pm, Wednesday, 15'th Apr 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue it
Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued
07:23pm, Friday, 10'th Apr 2026
On April 10, 2026, Anika Therapeutics Inc (ANIK) shares fell 3.1% to a current price of $14.76. This price is within a 52-week range of $7.87 to $15.48, indicat
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 03'rd Apr 2026
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early int
Top 2 Health Care Stocks That May Crash This Quarter
08:55am, Wednesday, 04'th Mar 2026
As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
01:57pm, Thursday, 26'th Feb 2026
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
01:16pm, Thursday, 26'th Feb 2026
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago.
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
07:05am, Thursday, 26'th Feb 2026
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 mil
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average – Here’s What Happened
04:48am, Thursday, 19'th Feb 2026
Anika Therapeutics Inc. (NASDAQ: ANIK - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.41 and traded as high
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
04:01pm, Wednesday, 18'th Feb 2026
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, Pr
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
04:01pm, Thursday, 12'th Feb 2026
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
08:00pm, Friday, 23'rd Jan 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning t
